Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
Yearly lenacapavir injection for HIV prevention shows safety and long-lasting effects, according to clinical trial results.
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
4d
MedPage Today on MSNOnce-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly DosingA once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results